Activated interferon response from DNA damage in multiple myeloma cells contributes to the chemotherapeutic effects of anthracyclines

被引:1
|
作者
Li, Jin [1 ]
Jia, Zhuxia [1 ]
Wang, Rongxuan [1 ]
Xiao, Bitao [1 ]
Cai, Yanan [1 ]
Zhu, Tianshu [1 ]
Wang, Weiya [1 ]
Zhang, Xinyue [1 ]
Fan, Shu [1 ]
Fan, Xiaolong [2 ]
Han, Wenmin [1 ]
Lu, Xuzhang [1 ]
机构
[1] Nanjing Med Univ, Changzhou 2 Peoples Hosp, Affiliated Hosp, Dept Hematol, Changzhou, Peoples R China
[2] Beijing Normal Univ, Beijing Key Lab Gene Resource & Mol Dev, Lab Neurosci & Brain Dev, Beijing, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2024年 / 14卷
关键词
multiple myeloma; DNA damage response; doxorubicin; drug resistance; type 1 interferon (IFN-I); GAMMA-H2AX; ALPHA; RADIATION; MARKER;
D O I
10.3389/fonc.2024.1357996
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Multiple myeloma (MM) is a malignant plasma cell disease caused by abnormal proliferation of clonal plasma cells in bone marrow. Upfront identification of tumor subgroups with specific biological markers has the potential to improve biologically-driven therapy. Previously, we established a molecular classification by stratifying multiple myeloma into two subtypes with a different prognosis based on a gene module co-expressed with MCL-1 (MCL1-M).Methods Gene Ontology (GO) analysis with differentially expressed genes was performed to identify signal pathway. Drug sensitivity was analyzed using the OncoPredict algorithm. Drug sensitivity of different myeloma cell lines was detected by CCK8 and flow cytometry. RNA-seq was performed on drug-sensitive cell lines before and after adriamycin treatment. RT-qPCR was used to further verify the sequencing results. The expression of gamma-H2AX and dsDNA in sensitive and resistant cell lines was detected by immunofluorescence method.Results In our study, we demonstrated that MCL1-M low MM were more sensitive to anthracyclines. We treated different myeloma cell lines with doxorubicin in vitro and discovered the association of drug sensitivity with IFN signaling. Herein, we demonstrate that the doxorubicin-sensitive myeloma cell line showed significant DNA damage and up-regulated expression of genes related to the IFN response, which was not observed in drug-insensitive cell lines.Discussion Our results suggest that the active IFN signaling pathway may serve as a marker for predicting chemotherapy sensitivity in patients with myeloma. With our MCL1-M molecular classification system, we can screen patients with a potentially good response to the interferon signaling pathway and provide individualized treatment for MM. We propose IFN-a as adjuvant therapy for patients with myeloma sensitive to anthracyclines to further improve the therapeutic effect and prolong the survival of patients.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Interferon signaling is activated in response to DNA damage
    Brzostek-Racine, Sabrina
    Gordon, Chris
    VanScoy, Sarah
    Reich, Nancy C.
    CYTOKINE, 2009, 48 (1-2) : 12 - 12
  • [2] Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
    Petrilla, Cole
    Galloway, Joshua
    Kudalkar, Ruchi
    Ismael, Aya
    Cottini, Francesca
    CANCERS, 2023, 15 (16)
  • [3] Targeting Ongoing Dna Damage in Multiple Myeloma: effects of Dna Damage response inhibitors on Plasma cell survival
    Belen Herrero, Ana
    Carmen Gutierrez, Norma
    FRONTIERS IN ONCOLOGY, 2017, 7
  • [4] Pim2 is important for regulating DNA damage response in multiple myeloma cells
    J Ramachandran
    L Santo
    K T Siu
    C Panaroni
    N Raje
    Blood Cancer Journal, 2016, 6 : e462 - e462
  • [5] Pim2 is important for regulating DNA damage response in multiple myeloma cells
    Ramachandran, J.
    Santo, L.
    Siu, K. T.
    Panaroni, C.
    Raje, N.
    BLOOD CANCER JOURNAL, 2016, 6 : e462 - e462
  • [6] MMSET Contributes to Multiple Myeloma Oncogenesis Through Induction of Global Epigenetic Changes and Alteration of the DNA Damage Response
    Popovic, Relia
    Martinez-Garcia, Eva
    Sweet, Steve M. M.
    Zheng, Yupeng
    Kelleher, Neil L.
    Licht, Jonathan D.
    BLOOD, 2011, 118 (21) : 1483 - 1484
  • [7] DNA Damage Response in Multiple Myeloma: The Role of the Tumor Microenvironment
    Saitoh, Takayuki
    Oda, Tsukasa
    CANCERS, 2021, 13 (03) : 1 - 22
  • [8] Targeting Ongoing DNA Damage in Multiple Myeloma. Effects of Different Inhibitors of the DNA Damage Response on Plasma Cell Survival
    Herrero, Ana B.
    Gutierrez, Norma C.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E100 - E100
  • [9] ERβ sensitizes NSCLC cells to chemotherapeutic agents by regulating DNA damage response
    Bado, Igor
    Nikolos, Fotis
    Gustafsson, Jan-Ake
    Thomas, Christoforos
    CANCER RESEARCH, 2016, 76
  • [10] Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells
    Cea, Michele
    Cagnetta, Antonia
    Adamia, Sophia
    Acharya, Chirag
    Tai, Yu-Tzu
    Fulciniti, Mariateresa
    Ohguchi, Hiroto
    Munshi, Aditya
    Acharya, Prakrati
    Bhasin, Manoj K.
    Zhong, Lei
    Carrasco, Ruben
    Monacelli, Fiammetta
    Ballestrero, Alberto
    Richardson, Paul
    Gobbi, Marco
    Lemoli, Roberto M.
    Munshi, Nikhil
    Hideshima, Teru
    Nencioni, Alessio
    Chauhan, Dharminder
    Anderson, Kenneth C.
    BLOOD, 2016, 127 (09) : 1138 - 1150